M
etastatic melanoma is a deadly disease with a 5-year survival rate lower than 20%. 1 In 2011, ipilimumab, a fully humanized antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) was approved by the US Food and Drug Administration based on improved survival in a pivotal trial. 2 CTLA4 is a molecule on cytotoxic T-lymphocytes that plays a critical role in attenuating immune responses. Ipilimumab blocks the binding of B7, the ligand of CTLA4, thereby blocking the activation of CTLA4 and sustaining antitumor immune responses. Te time course to response can be variable with immunotherapeutics. We report on a patient who experienced a considerable delay before responding to ipilimumab.
Case presentation
A 27-year-old man with metastatic melanoma was initially treated with 11 cycles of paclitaxel plus carboplatin, but demonstrated progressive disease. In June 2010, he was found to have a mass that had eroded into his descending colon and a mass in the occipital region of the scalp (Figure) . Te abdominal mass was resected and he was started on ipilimumab in August 2010 on the expanded-access protocol. www.jcso-online.com Case Report ted for further evaluation. No infectious etiology was found for his diarrhea, and it was attributed to the ipilimumab. He received methylprednisolone sodium succinate (125 mg) twice daily and was then transitioned to prednisone (1 mg/kg) after diarrhea resolved to grade 1.
At 7 days after discharge, his diarrhea recurred with associated abdominal pain while he was receiving prednisone. Te patient was admitted; his diarrhea improved on methylprednisolone sodium succinate but the abdominal pain persisted. A colonoscopy demonstrated a chronic active ileitis/colitis with scattered areas of ulceration. He was started on infiximab (5 mg/kg) and his symptoms resolved within 48 hours. He was discharged on prednisone (1 mg/ kg) and budesonide 3mg by mouth 3 times a day. He was given a second dose of infiximab (5 mg/kg) 3 weeks after discharge when his diarrhea worsened to grade 2. His prednisone was slowly tapered and fnally discontinued in February 2011. In March 2011, the imaging studies revealed hilar, peripancreatic lesions ( Figure) . Budesonide was discontinued in April 2011. Also in April 2011, he had a recurrence at the site of the previous resection, and the recurring lesion was resected. Imaging studies in June 2011 showed improvement of the occipital and peripancreatic lesions and worsening of the hilar lesion, which resolved on subsequent scans (Figure) . Scans in March 2013 showed the patient to be in complete remission (Figure) . Te patient did not receive any other therapy for his melanoma after the ipilimumab.
Discussion
Clinical studies of ipilimumab have demonstrated maximum disease control rates of about 35%, and durable disease control in up to 14% of patients. Te pivotal study has noted 12-and 24-month survival rates of 45.6% and 23.5%, respectively.
2 Yet because of the ipilimumab's side efect profle, some of these patients may require treatment with immunosuppressive drugs, which leads to a decreased overall survival rate. 3 Tis patient's imaging showed disease progression 8 months after therapy initiation, while he was still on glucorticoids, before showing partial response 11 months after treatment. Tis is not the pattern or tempo of response seen with conventional cytotoxic agents. Delayed response with ipilimumab has been shown in other studies, even with a 100% increase in tumor burden before response. 4 Te signs of apparent progressive disease are hypothesized to be the result of infltration of the tumor by immune cells, rather than actual disease progression. Tese unique response patterns have led to the development of proposed Immune-Related Response Criteria (irRC) for evaluation of efcacy with immunotherapy. Although this case represents an uncommon situation, it highlights the difculty in determining when a patient has truly failed ipilimumab treatment. Given the variability of responses with ipilimumab, we would recommend any physician using this agent consider the irRC before discontinuing treatment.
